PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
738.04%
R&D growth above 1.5x AGEN's 38.01%. Michael Burry would check for spending discipline.
40.95%
Similar G&A growth to AGEN's 53.11%. Walter Schloss would investigate industry cost structures.
No Data
No Data available this quarter, please select a different quarter.
-9.94%
Other expenses reduction while AGEN shows 2003.56% growth. Joel Greenblatt would examine efficiency.
178.81%
Operating expenses growth above 1.5x AGEN's 53.11%. Michael Burry would check for inefficiency.
178.81%
Total costs growth above 1.5x AGEN's 45.56%. Michael Burry would check for inefficiency.
No Data
No Data available this quarter, please select a different quarter.
-9.94%
D&A reduction while AGEN shows 92.88% growth. Joel Greenblatt would examine efficiency.
-184.06%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-178.81%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-185.77%
Other expenses reduction while AGEN shows 2001.28% growth. Joel Greenblatt would examine advantage.
-184.01%
Pre-tax income decline while AGEN shows 93.80% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-184.01%
Net income decline while AGEN shows 93.80% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-184.12%
EPS decline while AGEN shows 95.68% growth. Joel Greenblatt would examine position.
-184.12%
Diluted EPS decline while AGEN shows 95.68% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.